Armata Pharmaceuticals Inc (ARMP)

$3

-0.02

(-0.66%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.95
    $3.17
    $3.00
    downward going graph

    1.67%

    Downside

    Day's Volatility :6.94%

    Upside

    5.36%

    downward going graph
  • $1.15
    $5.26
    $3.00
    downward going graph

    61.67%

    Downside

    52 Weeks Volatility :78.14%

    Upside

    42.97%

    downward going graph

Returns

PeriodArmata Pharmaceuticals IncIndex (Russel 2000)
3 Months
19.52%
0.0%
6 Months
-22.68%
0.0%
1 Year
150.0%
0.0%
3 Years
-22.48%
-19.4%

Highlights

Market Capitalization
109.2M
Book Value
- $1.56
Earnings Per Share (EPS)
-2.2
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
-1058.8%
Return On Assets TTM
-21.7%
Return On Equity TTM
-3439.35%
Revenue TTM
4.7M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
21.4%
Gross Profit TTM
-29.5M
EBITDA
-38.7M
Diluted Eps TTM
-2.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.9
EPS Estimate Next Year
-1.3
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Armata Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 166.67%

Current $3.00
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Armata Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc
6.11%
-22.68%
150.0%
-22.48%
-10.45%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc
NA
NA
NA
-1.9
-34.39
-0.22
NA
-1.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc
Buy
$109.2M
-10.45%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Armata Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.52M → 966.0K (in $), with an average decrease of 36.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -19.84M → -25.02M (in $), with an average decrease of 26.1% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 223.1%

Company Information

c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com

Organization
Armata Pharmaceuticals Inc
Employees
66
CEO
Dr. Mina Pastagia M.D., MS
Industry
Biotechnology

FAQs